ReviewImmunologic research1998
Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.
Review in Immunologic research, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and acute rejection risk in transplant recipients.Molecular biology reports · 2012Pooled it
- Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.Signal transduction and targeted therapy · 2025Review
- Immunotherapy-Related Hypophysitis: A Narrative Review.Cancers · 2025Review
- Photothermal therapies to improve immune checkpoint blockade for cancer.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2020Review
- Itch regulation of innate and adaptive immune responses in mice and humans.Journal of leukocyte biology · 2020Review
- NK Cell-Based Immune Checkpoint Inhibition.Frontiers in immunology · 2020Review
- Identifying and managing the adverse effects of immune checkpoint blockade.Journal of thoracic disease · 2018Review
- Targeting Angiotensin II Type-1 Receptor (ATFrontiers in cellular and infection microbiology · 2017Article
- Current and emerging treatment options in the management of lupus.ImmunoTargets and therapy · 2016Review
- Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications.Therapeutic advances in musculoskeletal disease · 2015Review
- Novel therapeutic agents in clinical development for systemic lupus erythematosus.BMC medicine · 2013Review
- Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Costimulatory molecules of the B7 family regulate the activation of T lymphocytes. T cell activation is promoted by binding of B7 molecules to CD28 and inhibited by binding to CTLA-4 (CD152). The balance between positive signals through CD28 and negative signals through CTLA-4 is critical for the fate of the T cell and is subject to tight regulation. Recent in vitro and in vivo studies have significantly advanced our understanding of the function of the CTLA-4 receptor. The results of these experiments suggest that CTLA-4 is critical for the induction of self-tolerance, and that it may have distinct signaling functions in resting and activated T cells. In resting T cells, CTLA-4 crosslinking leads to cell-cycle arrest, whereas in activated T cells, CTLA-4 crosslinking induces apoptosis. In this article, we will review the physiologic functions of the CTLA-4 receptor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.